Sickle cell blood study pulled before it began
NCT ID NCT07155031
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to see how long specially treated red blood cells survive in adults with sickle cell disease who receive regular blood exchange therapy. It was withdrawn before any participants were enrolled, so no results are available. The goal was to better understand the lifespan of these cells to improve future transfusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Co-Designed support help parents embrace sickle cell care?
- Can community hospitals in zambia master severe disease care?
- A Pocket-Sized coach for sickle cell: can an app turn Pill-Taking into a habit?
- Can a phone app keep teens on track with sickle cell treatment?
- A common amino acid may calm sickle cell pain crises — a trial puts it to the test
- A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease